Skip to main content

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Lluis Castells Fusté

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Estudi de tolerància perifèrica a la proteïna no estructural NS3 del virus de l'hepatitis C (VHC) per desenvolupar immunoteràpia contra la infecció per VHC per a la prevenció de l'hepatocarcinoma

IP: Juan Ignacio Esteban Mur
Collaborators: Lluis Castells Fusté, Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Fundació La Marató de TV3
Funding: 165000
Reference: TV3/052310
Duration: 01/01/2006 - 31/12/2009

Infección y trasplante. Consolidación de RESITRA en el marco RETICS. Explotación de la cohorte RESITRA

IP: Albert Pahissa Berga
Collaborators: Lluis Castells Fusté, Joan Gavaldà Santapau, Isabel Ruiz Camps
Funding agency: Instituto de Salud Carlos III
Funding: 47124
Reference: PI051227
Duration: 01/01/2006 - 31/12/2006

Selección y expansión de linfocitos T CD4+ NS3-específicos de pacientes infectados por Virus de la hepatitis C (VHC). Caracterización del estado de anergia de la infección crónica

IP: -
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Josep Quer Sivila, Juan Ignacio Esteban Mur
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 90750
Reference: SAF2006-03681
Duration: 01/10/2006 - 30/09/2009

Ministerio de Ciencia

TOH/VIH-05: Trasplante hepático en pacientes infectados por el VIH en España (2005-2007) TOH/VIH-09: Trasplante hepático en pacientes infectados por el VIH en España (2009-2011)

IP: Lluis Castells Fusté
Collaborators: Isabel Campos Varela
Funding agency: Fundación Innov. y Prosp. Salud en España - FIPSE
Funding: 76100
Reference: FIPSE/TOH/VIH
Duration: 01/02/2006 - 31/01/2012

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Selen Ozkan

Selen Ozkan

Predoctoral researcher
Clinical and Translational Bioinformatics
Read more
Maria Victoria Gonzalez Martinez

Maria Victoria Gonzalez Martinez

Senior researcher
Pediatric Neurology
Read more
Tamara Garcia Antolinez

Tamara Garcia Antolinez

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.